Prevalance of anti-HCV among hemodialysis and CAPD patients

Abstract

HCV infection is the most common cause of liver disease among dialysis patients. Patients with end stage renal disease are at risk of acquiring HCV infection from blood product transfusions, intravenous access or other patients in dialysis units. Continuous ambulatory peritoneal dialysis is getting popular among dialysis patients in our country. The aim of this study is to demonstrate anti-HCV frequency, liver enzyme levels and blood transfusion numbers among hemodialysis and CAPD patients. 41 hemodialysis patients (19 male, 22 female, mean age 36.6 years, mean hemodialysis duration 55.2 months) and 24 CAPD patients (7 male, 17 female, mean age 46.4 years, mean CAPD duration 10.0 months) were included to the study. This study shows the prevalence of anti-HCV and number of blood transfusion is lower in CAPD patients than in hemodialysis patients.